Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched

Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched

(1) Quizartinib is an oral tablet. The recommended dose is once daily, one tablet per day (the specific dose is determined by your doctor based on your body weight and renal function). Please take it at approximately the same time each day, with or without food, and swallow the tablet whole without cutting, crushing, or chewing.

(2) If you miss a dose on that day, take it as soon as possible on the same day; if it is nearly time for the next dose, skip the missed dose and take the next one as scheduled the following day. Never take a double dose on the same day. If vomiting occurs after taking the dose, do not take an additional dose; resume normal dosing the next day.

(3) During treatment, strictly follow your doctor's instructions and do not adjust the dose or stop treatment on your own. At the same time, please carry your medication information and emergency contact numbers with you at all times, so that timely medical care can be provided in case of cardiac emergencies.

(4) You can use the patient-physician communication guide to raise questions of concern to your doctor and enhance your confidence in treatment.

Risk Factors and Epidemiological Data for AML

(1) AML can occur at any age, but the incidence increases significantly in middle-aged and older adults, with a median age at first diagnosis of approximately 68 years. It is relatively uncommon in people under 45. Age is a non-modifiable risk factor, but advanced age alone is not an absolute causative factor.

(2) Other risk factors include: long-term exposure to certain chemicals (such as benzene), prior radiotherapy or chemotherapy (especially alkylating agents), having certain hematologic disorders (such as myelodysplastic syndromes), smoking, and having certain genetic syndromes (such as Down syndrome). However, most AML patients have no clearly identifiable risk factors.

(3) In the United States, there are approximately 20,000 new cases of AML each year. Although it is one of the most common types of adult leukemia, it remains rare among all cancers overall. Because AML progresses rapidly, early diagnosis and timely intervention are critically important.

(4) Understanding these data helps patients face the disease realistically, but more importantly, the disease can occur even without risk factors, so any abnormal symptoms (such as persistent fever, fatigue, bruising, etc.) should not be ignored, and prompt medical evaluation should be sought.

The Three Treatment Phases of Quizartinib: Induction, Consolidation, and Maintenance

(1) Treatment for AML is generally divided into three phases. The induction phase is the first stage, aimed at rapidly clearing leukemia cells from the blood and bone marrow to achieve complete remission. This phase typically uses intensive chemotherapy combined with quizartinib, and patients generally require hospitalization.

(2) The consolidation phase is the second stage. Even after achieving remission with induction, minimal residual leukemia cells may still be present in the body, so several cycles of chemotherapy (with or without targeted agents) are needed to further eliminate these residual cells and reduce the risk of relapse. Consolidation usually involves cyclical dosing with rest days in between for recovery.

(3) The maintenance phase is the third stage. The goal of this phase is to prolong remission, prevent relapse, and improve long-term survival. After consolidation therapy ends, quizartinib can be used alone as maintenance treatment, taken orally daily for an extended period. However, it should be noted that if a patient has undergone hematopoietic stem cell transplantation, quizartinib should not be used alone for maintenance therapy.

(4) Throughout the entire treatment process, the doctor will flexibly adjust the dose of quizartinib based on blood counts, electrocardiograms, and side effects to ensure a balance between efficacy and safety.